For investors who want to find safe plays amid a volatile market, there's a whole set of large-cap names — particularly in health care — that could make for attractive investments. Stocks had a wild few trading sessions after Monday's steep global sell-off, and closed the week up at levels that almost reversed its weekly losses. The three major U.S. indexes initially tumbled on weaker-than-expected U.S.
Second-quarter global net revenue for Humira, which treats severe rheumatoid arthritis, Crohn's disease, and ulcerative colitis, fell 29.8% from the same quarter in 2023, as competition from cheaper biosimilars continues to weigh on sales. However, some of the patients are moving to AbbVie's immunology treatments Skyrizi and Rinvoq, the company's management has said.